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Abstract Background When prescribing medications,
physicians should recognize clinically relevant potential
drug–drug interactions (DDIs). To improve medication
safety, it is important to understand prescribers’ knowledge
and opinions pertaining to DDIs. Objective To determine the
current DDI information sources used by medical residents,
their knowledge of DDIs, their opinions about performance
feedback on co-prescription of interacting drugs. Setting
Academic hospitals of Mashhad University of Medical Sci-
ences (MUMS) in Iran. Methods A questionnaire containing
questions regarding demographic and practice characteris-
tics, DDI information sources, ability to recognize DDIs, and
opinions about performance feedback was distributed to
medical residents of 22 specialties in eight academic hospi-
tals in Iran. We analyzed their perception pertaining to DDIs,
their performance on classifying drug pairs, and we used a
linear regression model to assess the association of potential
determinants on their DDI knowledge. Main Outcome Mea-
surePrescribers’ knowledge and opinions pertaining to DDIs.
ResultsThe overall response rate and completion rate for 315
distributed questionnaires were 90% (n = 295) and 86%
(n = 281), respectively. Among DDI information sources,
books, software on mobile phone or tablet, and Internet were
the most commonly-used references. Residents could cor-
rectly classify only 41% (5.7/14) of the drug pairs. The
regression model showed no significant association between
residents’ characteristics and their DDI knowledge. An
overwhelming majority of the respondents (n = 268, 95.4%)
wished to receive performance feedback on co-prescription
of interacting drugs in their prescriptions. They mostly
selected information technology-based tools (i.e. short text
message and email) as their preferred method of receiving
feedback. Conclusion Our findings indicate that prescribers
may have poor ability to prevent clinically relevant potential
DDI occurrence, and they perceive the need for performance
feedback. These findings underline the importance of well-
designed computerized alerting systems and delivering per-
formance feedback to improve patient safety.
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Impacts on practice
• In view of the residents’ knowledge deficits concerning
DDIs and the high prevalence of potential DDIs in
physicians’ prescriptions, it is recommended that tar-
geted interventions, such as educational programs, be
used to improve prescribers’ knowledge.
• The high number of interacting drug combinations and
limited ability of prescribers to identify them under-
score the need for a (computerized) alerting systems
which aid prescribers in recognition of potential DDIs.
• Access to electronic sources for DDIs, such as Internet
and software on mobile devices, should be further
facilitated in clinical settings.
• Prescribers stated interest in receiving feedback about
interacting drugs in their prescriptions and their desire
to receive such information via email and short
messages. Hence, policy makers should make decisions
about the use of this type of technology based
interventions to improve patient safety.
Introduction
Drug–drug interactions (DDIs) are an important type of
preventable adverse drug events (ADEs) which can lead
to patient hospitalization or even death [1–3]. Due to the
significant use of medications in medical therapy, it is
essential that physicians can recognize potential DDIs.
Given the ever-changing and expanding information
about medications, it is difficult for prescribers to take
DDI-relevant information into account when prescribing
drugs [4]. So far, different strategies have been used to
assist prescribers in identifying potential DDIs. Providing
educational interventions [5, 6], facilitating access to
DDI information sources [7], applying computerized
alerting systems [8, 9], and delivering performance
feedback [10–13] are among the most commonly used
strategies.
To choose and apply the most appropriate strategy, it
may be helpful to determine the level of targeted pre-
scribers’ DDI knowledge, their opinions on DDIs and the
usefulness of related information sources, and also the
factors that may be associated with their ability to recog-
nize potential DDIs.
Previous studies have unanimously reported that pre-
scribers’ knowledge of DDIs is generally poor [14–16]. In
a survey about prescribers’ DDI knowledge in the US [15],
only 42.7% of all drug pairs were categorized correctly by
prescribers, and among demographic and practice factors
only specialty and the degree of attention to DDI risk were
related to prescribers’ DDI knowledge [15]. In a similar
survey, 44% of drug pairs were correctly categorized by
Veterans Affairs clinicians [14]. Another study in the US
showed that the ability of pharmacy and medical students
in identifying important DDIs was poor [16].
In Iran prescriptions are mainly written on paper and
there is no systematic mechanism (e.g. electronic pre-
scribing system) to prevent DDIs. The results of a sys-
tematic review showed that the incidence of potential DDIs
in Iran is relatively high [17]. To reduce potential DDIs in
physicians’ prescriptions by means of information tech-
nology-based feedback, a multiphase project was estab-
lished in Mashhad, Iran. Since medical residents are
usually the frontline in the inpatient medical team during
the patient visit, their medication knowledge should be
sufficient. In this phase of the project, we assessed medical
residents’ knowledge and opinions on potential DDIs.
Aim of the study
(1) To assess how well medical residents recognize clini-
cally relevant potential DDIs; (2) to determine the current
DDI information sources used by residents, their desire to
receive performance feedback on co-prescription of inter-
acting drugs in their prescriptions, and their preferences on
method of receiving feedback.
Ethics approval
This study was approved by the Ethical Committee for
Research in Mashhad University of Medical Sciences
(MUMS) (Reference no. 931174, date: June 11, 2014).
Methods
Study design and setting
This cross-sectional, descriptive, and analytic study was
conducted at MUMS, Iran, in 2014. The study population
included all residents of 22 specialties (650 residents) in
eight academic hospitals of MUMS. Sample size (n = 242)
was determined by Krejcie and Morgan’s table (based on a
required confidence interval of 95%, and margin of error at
5%) [18], which is a common method of determining the
representative sample size needed for a survey. Propor-
tional stratified random sampling was used for sample
selection.
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Questionnaire and data collection
A survey questionnaire was developed based on the work
of Ko et al. [15]. The questionnaire contained four sets
of questions: (a) 10 demographic questions regarding
characteristics of the residents and their practice; (b) 12
questions concerning the residents’ opinions about DDIs
and related information sources; (c) a 14-item DDI
knowledge test; (d) four questions regarding the resi-
dents’ opinions about performance feedback to reduce
DDIs. Demographic and performance feedback questions
were developed by an expert panel for the purposes of
this study. Opinion and knowledge test questions were
adopted from the previous study [15]. The process of
translation and back-translation for these adapted ques-
tions were carried out from English to Persian and vice
versa. Opinion questions were about the prescribers’
perceptions about quality of DDI information provided
by various sources and risk of DDIs for patients. The
participants were requested to respond based on their
perceptions on a five-point Likert scale. The DDI
knowledge test consisted of 14 drug pairs which included
four pairs that should not be used together, two pairs that
may be used together but with monitoring, and eight
pairs that could be used safely together. The content
validity of the questionnaire was evaluated by 12 experts
(six pharmacists, and six medical doctors and specialists)
based on healthcare setting in Iran. They rated the level
of representativeness and clarity of each item on a scale
of 1–4 (1: ‘do not agree’, 4: ‘completely agree’) [19].
The content validity index (CVI) of measures was cal-
culated for each item by computing the proportion of
experts who considered the item as content-wise valid
(‘agree’ or ‘completely agree’). The average CVIs of
both validity measures were greater than 0.8. Although
the reliability of the questionnaire was confirmed in a
previous study [20], we conducted a pilot test on 50
residents and used Cronbach’s alpha to assess the inter-
nal consistency. Cronbach’s alpha coefficients of the
opinion and knowledge questions (0.72 and 0.87,
respectively) were well above the limit of 0.70 suggested
by Nunnally [21].
The first author participated in morning reports and
journal clubs, described the purpose of the survey and the
questionnaire to residents, and assured them that all
information would be completely confidential. Residents
who agreed to participate were given the questionnaire and
asked to complete it anonymously without using any ref-
erences or assistance. Because one of the main purposes of
this study was to assess how well participants recognize
clinically relevant potential DDIs, they were not allowed to
use references or assistance when answering knowledge
tests (unlike in clinical situations in which physicians have
access to various information sources).
Statistical analysis
Frequencies and percentages were used to describe cate-
gorical variables. The relationship between residents’
opinions concerning the usefulness of DDI information
source and their usual source of DDI information was
examined using Kruskal–Wallis test. The association
between each potential determinant (originating from res-
idents’ characteristics) and residents’ DDI knowledge was
assessed using univariate linear regression model. Then
confounders of the association were identified with the
10% change point of estimation rule based on the analytical
model proposed by Jorgensen et al. [22]. Finally, each
potential determinant and identified confounders were
entered in a multivariate linear regression model. Statistical
analysis was performed using SPSS statistical software
(version 20, SPSS, Inc.).
Results
Characteristics of the sample
In total, 326 residents participated in morning reports and
journal clubs. A total of 315 questionnaires were dis-
tributed among residents, out of which 295 were returned
back (the response rate = 90%). There were 281 ques-
tionnaires were deemed suitable for analysis (the comple-
tion rate = 86%). Table 1 lists the respondents’
demographic and practice characteristics.
Residents’ sources of information and their general
opinions about DDI
When more information was needed about a DDI, the
respondents most commonly used a book (n = 120,
42.7%), software on mobile or tablet (n = 94, 33.5%), and
Internet (n = 43, 15.3%) (Table 2). Overall, 203 (72.2%)
and 166 (59.1%) of the respondents reported that DDI
information was usually or always useful to them in future
prescribing and sufficient for them to manage the interac-
tion, respectively (Table 3). More than half of the
respondents (n = 154, 54.9%) reported that when they
consulted a source, DDI information changed their initial
prescribing decisions. Kruskal–Wallis results indicated no
significant differences between residents’ three information
source groups (clinicians, printed materials, and electronic
sources) for five statements about their opinions concerning
the usefulness of DDI information sources.
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Prescribers’ opinions about risk of DDI
While the majority of the respondents (n = 230, 81.8%)
usually or always asked patients about their use of pre-
scription drugs, about half of them (n = 137, 48.7%) asked
about their use of over-the-counter (OTC) products
(Table 4). Most of the respondents believed that the risk of
DDI affected their selection of drugs (n = 194, 69%) and
declared that they had seen a patient who had a drug
interaction that caused temporary or permanent harm
(n = 195, 69.4%). According to 187 (66.5%) of the
respondents, a DDI was more frequently caused by drugs
that were prescribed by multiple prescribers compared to
the same prescriber (n = 7, 2.5%) and self-medication by
patients (n = 82, 29.2%).
Residents’ ability to recognize potential DDIs
The average percentage of correctly classified drug pairs
was 41.5% ± 21.7. Among all the drug pairs, the pair
alprazolam and ketoconazole was the least-correctly clas-
sified pair (n = 31, 11%), while amoxicillin and
Table 1 Characteristics of the 281 respondents
Characteristic N (%)
Sex
Female 147 (52.3)
Male 131 (46.6)
Missing 3 (1.1)
Age range (year)
21–25 3 (1.1)
26–30 98 (34.9)
31–35 111 (39.5)
36–40 35 (12.5)
41–45 22 (7.8)
[46 5 (1.8)
Missing 7 (2.5)
Specialty
Anesthesia 17 (6)
Cardiology 18 (6.4)
Dermatology 10 (3.6)
Emergency medicine 39 (13.9)
Infectious 14 (5)
Internal medicine 28 (10)
Neurology 12 (4.3)
Neurosurgery 9 (3.2)
Nuclear medicine 5 (1.8)
Obstetrics and gynecology 23 (8.2)
Oncology 5 (1.8)
Ophthalmology 15 (5.3)
Orthopedics 11 (3.9)
Otolaryngology 11 (3.9)
Pediatrics 18 (6.4)
Psychiatric 17 (6)
Surgery 17 (6)
Urology 7 (2.8)
Occupational medicine 5 (1.8)
Years from graduation
\1 45 (16)
1–3 49 (17.4)
4–10 64 (22.8)
11–20 25 (8.9)
[20 1 (0.4)
Missing 97 (34.5)
Practice experience (year)
\1 30 (10.7)
1–3 78 (27.8)
4–10 82 (29.2)
11–20 35 (12.5)
[20 1 (0.4)
Missing 55 (19.6)
Number of practice sites
1 111 (39.5)
Table 1 continued
Characteristic N (%)
[1 115 (40.9)
Missing 55 (19.6)
Primary practice location
Office-based practice 13 (4.6)
Clinic 43 (15.3)
Hospital 217 (77.2)
Missing 8 (2.8)
Average working hours in practice per day (h)
1–3 20 (7.1)
4–6 98 (34.9)
7–9 60 (21.4)
[9 71 (25.3)
Missing 32 (11.4)
Average number of prescriptions per day
\20 128 (45.6)
20–30 65 (23.1)
31–40 29 (10.3)
[40 42 (19.4)
Missing 17 (6)
Average number of drugs per prescription
2 41 (14.6)
3 146 (52)
4 66 (23.5)
[4 13 (4.6)
Missing 15 (5.3)
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acetaminophen was the most-correctly classified one
(n = 245, 87.2%) (Table 5). More than 80% of the
respondents could not correctly identify the following two
contraindicated DDIs: ciprofloxacin ? theophylline
(n = 49, 17.4%) and alprazolam ? ketoconazole (n = 31,
11%)). Regarding two drug pairs that need monitoring,
only about one-third of the respondents categorized them
correctly. The average percentage of incorrectly classified
interacting drug pair (contraindicated or monitoring-re-
quired pair) as having no interaction (i.e. false-negative
error) was 12.2% ± 9.3. By contrast, the average per-
centage of incorrectly classified a non-interacting drug pair
as having interaction (i.e. false-positive error) was
19.2% ± 11.3.
Residents’ desire to receive performance feedback
Overall, 268 (95.4%) respondents wished to receive per-
formance feedback on co-prescription of interacting drugs
in their prescriptions. Regarding the time interval to
receive feedback, ‘at the end of the month’ was the most
preferred one (n = 110, 39.1%), followed by ‘at the end of
the week’ (n = 65, 23.1%), ‘dispense time’ (n = 42,
14.9%), and ‘at the end of the day’ (n = 31, 10.7%); the
least preferred time interval was ‘at the end of the
6 months’ (n = 20, 7.1%). A total of 265 respondents
(94.3%) selected at least one preferred method of receiving
feedback (Table 6). The majority of the respondents
(n = 166, 59.1%) selected short message service (SMS) as
their first preferred choice, followed by electronic mail
(email) (n = 68, 24.2%).
The results of the regression models
The results of the regression models (univariate and
multivariate) showed that no residents’ characteristics,
Table 2 Residents’ sources of DDI information
Source N (%)
Question: When you want to learn more about a DDI, what reference
do you use? (choose only one)
Pharmacist 5 (1.8)
Colleague (physician) 11 (3.9)
Book 120 (42.7)
Package insert 3 (1.1)
Internet 43 (15.3)
Software on mobile or tablet 94 (33.5)
Software on computer 1 (0.4)
Drug and poisoning information center 2 (0.7)
Othersa 2 (0.7)
Question: When one of your patients is about to be exposed to a
potential DDI, who usually informs you that the interaction may be
present?
Pharmacist 33 (11.7)
Computerized alert system 3 (1.1)
Mobile or tablet 70 (24.9)
Othersa 115 (40.9)
Missing 60 (21.4)
DDI drug–drug interaction
a ‘Others response’ refers to information resources other than phar-
macist, computerized alerting system or mobile-tablet
Table 3 Residents’ general opinions about their usual sources of DDI information
Questiona Usually and always N (%) P valueb
Overall Clinicians
(physician and
pharmacist)
Printed materials
(book and packet
insert)
Electronic sources (internet and
software on mobile, tablet, or
computer)
How often is the drug interaction
information new to you?
21 (7.5) 0 (0) 9 (7.5) 12 (8.6) 0.78
How often is the drug interaction
information relevant to the patient?
63 (22.8) 3 (18.8) 31 (25.5) 29 (21.2) 0.12
Is the drug interaction information
sufficient for you to manage the
interaction?
164 (59.2) 9 (56.3) 77 (62.6) 78 (56.5) 0.88
How often does the drug interaction
information change your initial
prescribing decisions?
152 (54.9) 7 (43.8) 70 (57.4) 75 (54.3) 0.46
How often is the drug interaction
information useful to you in future
prescribing?
201 (72.6) 13 (81.3) 92 (76.0) 96 (70.6) 0.45
DDI drug–drug interaction
a Choices for response: 1 = never, 2 = seldom, 3 = sometimes, 4 = usually, 5 = always
b Kruskal–Wallis test
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including demographic and practice characteristics and
workload (i.e. sex, graduation duration, number of
practice sites, primary practice location, average length
of practice per day, average number of prescriptions per
day, the risk of DDI affected prescriber’s selection of
drugs, prescriber had seen a patient suffering from
drug interaction), were associated with their DDI
knowledge.
Discussion
This survey found that among DDI information sources,
books, software on mobile or tablet, and Internet were the
most commonly-used references. Residents could correctly
classify only 41% of the drug pairs. An overwhelming
majority of the respondents desired to receive performance
feedback on co-prescription of interacting drugs in their
Table 4 Residents’ opinions about risk of DDI
Questiona Usually and always N (%)
How frequently do you ask patients about their use of prescription drugs? 230 (81.8)
How frequently do you ask patients about their use of OTC products? 137 (48.7)
How often does the risk for a drug interaction affect your selection of a drug product? 194 (69)
OTC over-the-counter
a Choices for response: 1 = never, 2 = seldom, 3 = sometimes, 4 = usually, 5 = always
Table 5 Residents’ responses regarding DDIsa [N (%b)]
Drug pair Should not be used together
(contraindicated)
May be used together,
but with monitoring
No interactions Not surec
Warfarin and cimetidine 103 (36.7) 122 (43.4) 14 (5) 42 (14.9)
Sildenafil and bupropion 67 (23.8) 43 (15.3) 54 (19.2) 117 (41.7)
Ciprofloxacin and theophylline 49 (17.4) 99 (35.2) 71 (25.3) 62 (22.1)
Cyclosporine and rifampicin 42 (14.9) 97 (34.5) 27 (9.6) 115 (40.9)
Warfarin and verapamil 28 (10) 61 (21.7) 99 (35.2) 93 (33.1)
Captopril and simvastatin 15 (5.3) 22 (7.8) 189 (67.3) 55 (19.6)
Amoxicillin and acetaminophen 1 (0.4) 11 (3.9) 245 (87.2) 24 (8.6)
Atenolol and ranitidine 3 (1.1) 27 (9.6) 195 (69.4) 56 (20)
Digoxin and clarithromycin 65 (23.1) 90 (32) 22 (7.8) 104 (37)
Glibenclamide and alendronate 10 (3.6) 44 (15.7) 81 (28.8) 146 (52)
Sildenafil and isosorbide dinitrate 187 (66.5) 27 (9.6) 9 (3.2) 58 (20.6)
Zolpidem and metformin 6 (2.1) 44 (15.7) 106 (37.7) 125 (44.5)
Losartan and isosorbide dinitrate 11 (3.9) 38 (13.5) 105 (37.4) 127 (45.2)
Alprazolam and ketoconazole 31 (11) 88 (31.3) 62 (22.1) 100 (35.6)
a Numbers in bold type represent correct answers
b Due to rounding, percentages may not add to 100
c Missing data were considered as ‘not sure’
Table 6 Frequencies and
percentages of residents’
preferred methods to receive
performance feedback
Choice to receive feedback First choice Second choice Third choice
N (%)
Short message service (SMS) 166 (59.1) 13 (4.6) 12 (4.3)
Electronic mail 68 (24.2) 56 (19.9) 26 (9.3)
Web site 13 (4.6) 31 (11) 44 (15.7)
Phone 10 (3.6) 15 (5.3) 10 (3.6)
Postal mail 8 (2.8) 6 (2.1) 9 (3.2)
Missing 16 (5.7) 160 (56.9) 180 (64.1)
Int J Clin Pharm (2017) 39:560–568 565
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prescriptions. They mostly selected information technol-
ogy-based tools as preferred method of receiving feedback.
In this study, about half of the respondents used elec-
tronic sources to learn more about DDIs, while in a similar
study only 38% of prescribers had used this type of sources
[15]. A possible explanation for this might be that the
population in the present study has been relatively young
and people in this age group are usually interested in
information technology. In contrast to other findings
[15, 23], a small proportion of the respondents in our
survey (1.8%) reported that they ask a pharmacist when
they want to learn more about a DDI. It may be that the
participants in this study did not pay attention to the pivotal
role of clinical pharmacist in clinical care, though studies
conducted in Iran have shown that clinical pharmacists’
interventions effectively prevent medication errors
[24–27].
Our findings on residents paying attention to asking
patients about the use of prescription drugs compared to
over-the-counter (OTC) products are in agreement with Ko
et al.’s findings [15], which showed that prescribers asked
patients about the use of OTC products less frequently than
the use of prescription drugs. A possible explanation for
this might be that prescribers pay attention to the risk of
interaction between drugs and OTC products less than the
interaction between two prescribed drugs. However, pre-
scribers should consider that OTC products are frequently
used for self-medication by patients and some of them may
have interaction with prescription drugs [28–32]. Similar to
Ko et al.’s results, most of the prescribers perceived that
prescription by multiple prescribers is the main cause of
interactions [15]. Electronic medical record systems, which
automatically provide alerts on interactions between drugs
prescribed for the patient, have the potential to solve this
problem [7, 8].
The level of prescribers’ knowledge on DDI is insuffi-
cient and our findings are comparable to others (our study:
41.45%, [15]: 42.7%, [14]: 44%). There are some differ-
ences between these studies. Unlike our study, in the study
of Glassman et al. [14] the clinicians were allowed to use
information sources when answering the knowledge test. In
addition, the drug pairs which were evaluated in our study
were the same as those in the study of Ko et al. [15], but
different than in the study of Glassman et al. [14]. The
authors in the previous study argued that the prescribers
who were knowledgeable about DDIs probably participated
more than those with lower DDI knowledge level (adjusted
response rate = 7.9%) [15]. In our study residents with
virtually all levels of DDI knowledge participated (adjusted
response rate = 86%).
In this study the residents were asked about six DDIs
that had been already considered clinically important by
experts [33]. In the case of identification of these clinically
important DDIs, our results were similar to those of a
previous study [15]. In our study and the previous one [15],
on average about 40% of respondents answered ‘‘not sure’’
and ‘‘no interaction’’ for these six clinically important
DDIs. The results of both studies on these clinically
important DDIs identically showed that, on the one hand,
two drug pairs that were less frequently identified com-
pared to others were Ciclosporin ? Rifampicin and
Alprazolam ? Itraconazole (more than half of the
respondents could not correctly identify them). On the
other hand, two drug pairs that were more frequently
identified compared to others were Sildenafil ? Isosorbide
mononitrate and Warfarin ? Cimetidine (more than three
quarters of the respondents correctly identified them).
Our results indicated that the vast majority of the tar-
geted residents were interested in receiving performance
feedback about co-prescription of interacting drugs in their
prescriptions. Probably due to availability of mobile
phones, most of the respondents selected short messages as
the most preferred method of receiving feedback. The
selection of email by the most of the respondents as the
second preferred method may be explained by the fact that
our study population was young adults and studies have
shown that younger people are likely more interested in
using technology [34].
Similar to two previous studies, linear regression anal-
ysis was developed to examine the association between
prescribers’ DDI knowledge scores and their demographic
and practice characteristics [14, 15, 35]. Glassman et al.
found that younger clinicians and those spending more
half-days in clinic correctly categorized more interacting
pairs [14]. Ko et al. indicated that the prescribers who
reported that the risk of DDI affected their drug selection
‘very much’ had a higher DDI knowledge than those who
reported that the risk affected their drug selection ‘a little’
or ‘not at all’ [15, 35]. Contrary to these previous studies,
regression models revealed no significant association
between residents’ characteristics (e.g. graduation duration,
average length of practice per day, and attention to the risk
of DDIs) and knowledge of DDIs. A possible explanation
for this is that probably our study population was homo-
geneous in terms of demographic and practice character-
istics. Therefore, to determine the association between
prescribers’ DDI knowledge and their characteristics, a
further study is required on a population with heteroge-
neous characteristics and sample size larger than that for
the current study.
Due to the nature of the questionnaire distribution, the
present study has two strengths compared to the previous
ones [14, 15]. The response rate was high, so we are
confident that residents with different levels of DDI
knowledge participated in the study. Since a researcher was
present when the participants filled out the questionnaire,
566 Int J Clin Pharm (2017) 39:560–568
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they did not use any references to answer the knowledge
test; whereas in the previous studies the researchers were
not aware about the condition under which the question-
naire was completed [14, 15]. Some limitations to this
survey need to be considered. The first limitation of this
study is related to the ‘Others’ response to the question
about who informs the residents that DDI may be present.
Whilst, a high proportion of the participants (41%) selected
this response, there is no data about these other sources. To
determine which these other sources are, further investi-
gation is needed. The included drug pairs in the knowledge
test were the same for all medical specialties. It is rec-
ommended that future studies assess prescribers’ knowl-
edge in each specialty area with medications that are
specific to that area. Another limitation of this study was
that the participants were not allowed to use information
sources when answering knowledge test; whilst, physicians
in clinical situations usually have access to various drug
information sources when prescribing. The last limitation is
that participants were not allowed to select more than one
option to answer the multiple choice questions in the
questionnaire. This limitation was accepted in order to
compare our results to previous study [15].
The findings of the present study have a number of
implications for practice. Regarding residents’ knowledge
deficits concerning DDIs, found in the present study and
the previous ones [14, 15], and high prevalence of potential
DDIs in physicians’ prescriptions [17, 36–39], it is rec-
ommended that targeted interventions, such as educational
programs, be used to improve prescribers’ knowledge. The
high number of interacting drug combinations and limited
ability of prescribers to identify them underscore the need
for computerized alerting systems which aid prescribers in
recognition of potential DDIs. Based on our results, elec-
tronic sources were used more than others to learn more
about potential DDIs. So, it is recommended that the access
to electronic sources in clinical settings be facilitated fur-
ther. Regarding the prescribers’ interest in receiving feed-
back about co-prescription of interacting drugs in their
prescriptions and their desire to receive via email and short
messages, policy makers should make decisions about the
use of this type of information technology-based
intervention.
Conclusion
Our findings and those of previous studies indicate that
prescribers may have poor ability to prevent occurrence of
DDIs. This underscores the need for computerized alerting
systems to assist prescribers in identifying potential DDIs.
Considering that most of the residents used electronic
sources more than other sources to learn about DDIs, it is
recommended that access to this type of sources in clinical
settings be facilitated further. Regarding the interest of the
participants to receive performance feedback, on their
performance on co-prescription of interacting medications,
via information technology-based tools such as short
message and email, it is suggested that this type of inter-
ventions be used to improve medication safety.
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